Erschienen in:
01.02.2011 | Melanomas
In Reply: Sentinel Lymph Node Biopsy in Melanoma
verfasst von:
Ulrike Leiter, MD, Claus Garbe, MD
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 2/2011
Einloggen, um Zugang zu erhalten
Excerpt
Di Georgi and colleagues propose that sentinel lymph node biopsy (SLNB) does not provide a real survival benefit and that the disease-free survival benefit is a result of lead-time bias. These are old arguments that have been repeatedly discussed in the literature.
1‐
7 A reiterative statement of these arguments does not make them truer. The only new idea in the letter of Di Georgi and colleagues is to designate the gain of disease-free survival time as lead-time bias that shows that they did not really understand the concept of lead time bias.
8‐
11 …